Analyst Reco. Bausch + Lomb Corporation

Equities

BLCO

CA0717051076

Market Closed - Nyse Other stock markets 04:00:02 2024-06-10 pm EDT			5-day change	1st Jan Change
15.01 ^USD	-2.02%		-2.47%	-12.02%

Jun. 03	Bausch + Lomb Brief: Launching "Clinically Proven" Nutritional Supplement for Dry Eyes in the United States	MT
Jun. 03	Bausch + Lomb Corporation Launches Blink? NutriTears® Clinically Proven Nutritional Supplement for Dry Eyes in the United States	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Bausch + Lomb Shares Rise After Morgan Stanley Upgrade	May. 06	MT
Morgan Stanley Upgrades Bausch + Lomb to Overweight From Equalweight, Raises Price Target to $18 From $16	May. 06	MT
Deutsche Bank Adjusts Bausch + Lomb Price Target to $14 From $18, Maintains Hold Rating	May. 02	MT
RBC Cuts Price Target on Bausch + Lomb to $18 From $20, Keeps Outperform Rating	Apr. 22	MT
RBC Ups PT on Bausch Health Companies to $12 From $9 Reflecting Upcoming Appellate Court Decisions & Potential BLCO Distribution, Maintains Sector Perform Rating	Apr. 05	MT
Barclays Raises Price Target on Bausch + Lomb to $18 From $17, Maintains Equalweight Rating	Feb. 26	MT
Wells Fargo Ups Price Target on Bausch + Lomb to $23 From $21, Maintains Overweight Rating	Feb. 22	MT
RBC Lifts Price Target on Bausch + Lomb to $20 From $19 After Better-Than-Expected Q4, Above-Consensus 2024 Revenue Guidance; Outperform Kept	Feb. 22	MT
RBC Trims Price Target on Bausch + Lomb to $19 From $20 Ahead of Q4 2023 Report, Keeps Outperform Rating	Feb. 09	MT
Evercore ISI Downgrades Bausch + Lomb to In Line From Outperform, Adjusts Price Target to $17 From $19	Jan. 04	MT
Stifel Initiates Bausch + Lomb With Hold Rating, $16 Price Target	Dec. 12	MT
Morgan Stanley Trims Price Target on Bausch + Lomb to $16 From $17, Maintains Equal-Weight Rating	Dec. 04	MT
RBC Trims Price Target on Bausch + Lomb to $20 From $21 Amid Foreign-Exchange Headwinds, Keeps Outperform Rating	23-10-23	MT
Morgan Stanley Adjusts Price Target on Bausch + Lomb to $18.50 From $20, Keeps Equalweight Rating	23-10-13	MT
Fitch Affirms Bausch Health, Bausch Health America's Ratings; Bausch + Lomb's Rating Maintained	23-10-04	MT
Moody's Rates Bausch + Lomb's New Secured Debt Instruments	23-09-12	MT
Fitch Assigns Rating to Bausch + Lomb's Secured Term Loan, Secured Bond; Up 1.4%	23-09-11	MT
Barclays Adjusts Price Target on Bausch + Lomb to $19 From $18, Maintains Equalweight Rating	23-08-03	MT
Needham & Co Maintains Hold Rating on Bausch + Lomb After Q2	23-08-02	MT
Toronto Stocks Drop Amid U.S. Credit-Rating Downgrade; Cameco Shares Down	23-08-02	DJ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Bausch + Lomb Corporation

Equities

BLCO

CA0717051076

Analyst Reco.

Filters